Atrion Reports First Quarter 2023 Results

Rhea-AI Summary

Atrion Corporation reported disappointing results for the first quarter of 2023. Revenues were $40.0 million, down 15% from the same period last year. Operating income was $4.5 million, a decrease of 56%, and net income was $3.5 million, down 59%. Diluted earnings per share were $1.98 compared to $4.71 in Q1 2022. The company attributes the decline to delayed deliveries from customers due to concerns about a global economic slowdown. Atrion Corporation has cash and investments totaling $26.3 million and expects additional requests to delay deliveries.

Positive

• Revenues for the first quarter of 2023 were down 15% compared to the same period last year.
• Operating income decreased by 56% in Q1 2023.
• Net income declined by 59% in the first quarter of 2023.
• Diluted earnings per share were $1.98 in Q1 2023, compared to $4.71 in the same period last year.
• Atrion Corporation has cash and short and long term investments totaling $26.3 million.
• The company expects to see additional requests to delay deliveries due to continued deferrals in the current quarter.

Negative

• None.

ALLEN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2023.

Revenues for the first quarter of 2023 totaled $40.0 million compared to $47.1 million for the same period in 2022. For the quarter ended March 31, 2023, operating income was $4.5 million, down $5.8 million from the comparable 2022 period, and net income was $3.5 million, down $5.0 million from the same period in 2022. First quarter 2023 diluted earnings per share were $1.98 compared to $4.71 for the first quarter of 2022.

Commenting on the results for the first quarter of 2023 compared to the prior year period, David Battat, President and CEO, stated, “This was an extremely disappointing quarter. We can report that we did not lose any major customers—in fact long-term supply agreements with large customers were executed during the just-concluded quarter—nor did we see any significant cancellations of orders. However, several customers unexpectedly pushed out deliveries of products, citing concerns that a global economic slowdown is impacting the speed at which their inventories will be brought to appropriate levels. Primarily as a result of delayed deliveries, our first quarter 2023 revenues were down 15%, operating income was down 56%, and net income was down 59% after taking into account weaker performance in our investment portfolio in the current-year quarter. Based on the continued deferrals we are seeing in the current quarter, we expect to see additional requests to delay deliveries.”

Mr. Battat concluded, “As of March 31, 2023, cash and short and long term investments totaled $26.3 million. A program of multi-year investments to improve our efficiency, quality and operations totaling about $41 million will be substantially complete in June 2023. With the implementation of these investments for our future, we are focused on rebuilding our positions in cash and short and long term investments in anticipation of future opportunities. We remain debt free.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com. 

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, Atrion's expectations regarding additional requests to delay deliveries of our products and the substantial completion in June 2023 of our program of multi-year investments to improve our efficiency, quality, and operations. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.    

Contact:		Cindy Ferguson
		Vice President and Chief Financial Officer
		(972) 390-9800

ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)

	Three Months Ended March 31,
	2023				2022
Revenues	$	39,993			$	47,138
Cost of goods sold		24,912				27,894
Gross profit		15,081				19,244
Operating expenses		10,611				8,994
Operating income		4,470				10,250
Interest and dividend income		240				137
Other investment income (loss)		(721	)			(240	)
Other income		10				25
Income before income taxes		3,999				10,172
Income tax provision		(514	)			(1,673	)
Net income	$	3,485			$	8,499
Income per basic share	$	1.98			$	4.73
Weighted average basic shares outstanding		1,762				1,799
Income per diluted share	$	1.98			$	4.71
Weighted average diluted shares outstanding		1,763				1,803

        

ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)

	Mar. 31,			Dec. 31,
ASSETS	2023			2022
	(Unaudited)
Current assets:
Cash and cash equivalents	$	4,563		$	4,731
Short-term investments		13,013			21,152
Total cash and short-term investments		17,576			25,883
Accounts receivable		19,424			23,951
Inventories		75,093			65,793
Prepaid expenses and other		2,496			3,770
Total current assets		114,589			119,397
Long-term investments		8,697			8,669
Property, plant and equipment, net		125,367			123,754
Other assets		12,776			12,892
	$	261,429		$	264,712
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities		17,171			18,098
Line of credit		--			--
Other non-current liabilities		5,617			7,073
Stockholders’ equity		238,641			239,541
	$	261,429		$	264,712

FAQ

What were Atrion Corporation's revenues in the first quarter of 2023?

Atrion Corporation's revenues for the first quarter of 2023 were $40.0 million.

How much did operating income decrease in Q1 2023?

Operating income decreased by $5.8 million, or 56%, in the first quarter of 2023 compared to the same period last year.

What was Atrion Corporation's net income in Q1 2023?

Atrion Corporation's net income in the first quarter of 2023 was $3.5 million, a decrease of $5.0 million, or 59%, from the same period in 2022.

What were the diluted earnings per share in Q1 2023?

The diluted earnings per share for Atrion Corporation in the first quarter of 2023 were $1.98, compared to $4.71 in the same period last year.

How much cash and investments does Atrion Corporation have?

As of March 31, 2023, Atrion Corporation has cash and short and long term investments totaling $26.3 million.

What does Atrion Corporation expect in terms of future deliveries?

Atrion Corporation expects to see additional requests to delay deliveries due to continued deferrals in the current quarter.